Xbrane Biopharma AB (publ) reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was SEK 15.63 million compared to SEK 2.55 million a year ago. Net loss was SEK 33.78 million compared to SEK 59.17 million a year ago. Basic loss per share from continuing operations was SEK 1.32 compared to SEK 2.58 a year ago. Diluted loss per share from continuing operations was SEK 1.32 compared to SEK 2.58 a year ago. Basic loss per share was SEK 1.35 compared to SEK 2.67 a year ago. Diluted loss per share was SEK 1.35 compared to SEK 2.67 a year ago.
For the six months, sales was SEK 22.82 million compared to SEK 5.09 million a year ago. Net loss was SEK 69.9 million compared to SEK 110.44 million a year ago. Basic loss per share from continuing operations was SEK 2.82 compared to SEK 4.79 a year ago. Diluted loss per share from continuing operations was SEK 2.82 compared to SEK 4.79 a year ago. Basic loss per share was SEK 2.79 compared to SEK 4.97 a year ago. Diluted loss per share was SEK 2.79 compared to SEK 4.97 a year ago.